Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Source: ClinicalTrials.gov NCT02192164 ↗Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Psoriasis Assessment and Severity Index (PASI) Score at Week 24 |
21.02093; 20.40769; -18.40349; -15.64615 | — |
| SECONDARY Change From Baseline in Psoriasis Assessment and Severity Index (PASI) Score at Week 12 |
-18.18837; -17.27692 | — |
| SECONDARY Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12 and 24 |
82.56; 76.92; 86.05; 69.23 | — |
| SECONDARY Percent Change From Baseline in Psoriasis Assessment and Severity Index (PASI) at Week 12 and 24 |
0.139; 0.168; 0.120; 0.257 | — |
Eligibility Criteria
Inclusion Criteria
Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator Patients who are scheduled by their dermatologist to initiate treatment with Etanercept
Exclusion Criteria
Previous or current treatment with antipsoriatic biologic drugs, such as etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab Chronic or acute infections requiring intravenous or oral anti-infectives within 14 days prior to the Baseline visit
Data sourced from ClinicalTrials.gov (NCT02192164). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.